#Uterine Cancer Drugs Market

[mrunalnerkarblog]

Uterine Cancer Drugs Market is Expected to Gain Popularity Across the Globe by 2028

Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

Uterine Cancer Drugs Market Drivers

Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Uterine Cancer Drugs Market - Regional Analysis

Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.

[unwelcome-ozian]

What information do you have about Johnson & Johnson?

Alza filed an NDA for the transdermal opioid analgesic product in December 1987 for post-operative use and for the relief of chronic cancer pain. Developed by J&J subsidiary Janssen Pharmaceutica, fentanyl has been marketed since 1968 under the Sublimaze brand. The drug is currently approved for I.V. administration and used primarily as a short-acting analgesic during anaesthesia. "This new drug delivery system will make it possible for the first time to use fentanyl . . . outside the operating room to control moderate to severe pain." Source

US opioids: Johnson and Johnson and drug distributors offer $26bn to end thousands of lawsuits. Source

The drug company Johnson & Johnson (J&J) has expressed regret after court documents unsealed in talcum powder litigation showed that it funded a 1971 study in which Pennsylvania prison inmates, most of them black, were injected subcutaneously with asbestos. Source

Asbestos Prisoner Study May Spell More Problems for Johnson & Johnson

WASHINGTON - Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.  The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion. Source

Johnson & Johnson paused all clinical trials of its experimental COVID-19 vaccine after a study participant became sick with an "unexplained illness."

Johnson & Johnson has suspended international trials of a drug in the same class as an experimental drug made by Portuguese pharmaceutical company Bial, whose tests in France left one person brain dead and five others hospitalised. Source

1982 - McNeil

Product Recalled - Tylenol (acetaminophen) capsules

Reason for Recall - Medicine laced with potassium cyanide (poison) resulting in several patient deaths.

2009 to 2011 - McNeil

Product Recalled - Several OTC medicines including Tylenol, Motrin, Benadryl, St. Joseph aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, Zyrtec Eye Drops (tens of millions of bottles)

Reason for Recall - Unpleasant smells causing nausea; tiny metal shards in liquid medicines; wrong ingredient levels

2010 - DePuy [Pinnacle Systems]

Product Recalled - ASR Hip Resurfacing System and ASR XL Acetabular System (metal-on-metal hip implants)

Reason for Recall - Metal poisoning (metallosis); loosening of the implant or joint dislocation; additional surgeries

2012 - Ethicon

Product Recalled - Gynecare Prolift Kit, Gynecare Prolift+M Kit, Gynecare TVT Secure and Gynecare Prosima Pelvic Floor Repair System Kit (transvaginal mesh implants)

Reason for Recall - Perforation of organs; vaginal bleeding and scarring; mesh erosion; severe pain

2014 - Ethicon

Product Recalled - Power Morcellators

Reason for Recall - Spread of uterine cancer; rapid progression of the disease; death

2019 – Johnson & Johnson

Product Recalled – 33,000 bottles of Johnson’s Baby Powder

Reason for Recall – The FDA found a small amount of asbestos — a known carcinogen — in a sample

Xarelto

Number of Lawsuits - 13,511

Injuries - severe, sometimes deadly bleeding events, blood clots, wound leaks, infection

J&J was involved in seven of 2017’s top ten health-care-related verdicts.

The company was also involved in the third-largest pharmaceutical settlement with the U.S. Department of Justice. In 2013, J&J paid the Justice Department more than $2.2 billion. The settlement resolved civil and criminal allegations involving Risperdal, Invega and Natrecor.

May 2017

J&J paid $33 million to most U.S. states and the District of Columbia. The states charged J&J with misrepresenting the manufacturing practices behind certain drugs. This included its Motrin products. These products were later recalled.

Oz

[healthcarediagnosticmarket]

Progesterone Market Key Player Analysis: Growth Insights and Forecasts , Business Strategies, Challenges and Future Demand 2033

Global Progesterone Market Growth and Trends – Straits Research

Straits Research is pleased to present its comprehensive report on the global Progesterone Market, detailing market size, growth projections, trends, and key insights. With a projected CAGR of 12.3% from 2024 to 2032, the market is set to experience substantial growth, increasing from USD 1.50 billion in 2024 to USD 4.14 billion by 2032.

Market Definition:

Progesterone is a vital hormone, predominantly used in hormonal therapies. It plays a key role in regulating the menstrual cycle, supporting pregnancy, and managing conditions like dysfunctional uterine bleeding and endometrial cancer. There is a significant demand for progesterone in various medical treatments, driving its growing market share.

The global progesterone market is expected to grow rapidly due to increasing adoption of progesterone-based therapies for conditions such as menstrual irregularities, hormonal imbalances, contraception, and cancer therapies. This surge is also bolstered by the growing awareness of women's health and rising healthcare spending worldwide.

Market Size and Forecast

In 2023, the global progesterone market was valued at USD 1.34 billion. As the demand for progesterone-based treatments continues to rise, the market is projected to expand from USD 1.50 billion in 2024 to an estimated USD 4.14 billion by 2032. This growth will be driven by increasing healthcare expenditures, evolving consumer preferences for hormonal therapies, and expanding awareness around reproductive health.

Key Trends in the Progesterone Market:

Rise in Hormonal Therapy Awareness: The increasing awareness about the benefits of hormonal therapies, especially progesterone in regulating menstrual cycles and treating various gynecological disorders, is propelling the market's growth.

Technological Advancements in Drug Delivery Systems: Advances in the development of new drug delivery systems, such as injectable and oral progesterone formulations, are improving treatment outcomes and ensuring better patient compliance.

Growing Use in Contraceptive Treatments: The application of progesterone in contraception, particularly in the form of intrauterine devices (IUDs) and oral contraceptives, is significantly boosting market growth.

Growth Factors:

The progesterone market is witnessing substantial growth due to several driving factors:

Increasing Incidence of Hormonal Disorders: The rise in conditions like irregular menstrual cycles, menopause, and polycystic ovary syndrome (PCOS) is fueling the demand for progesterone-based treatments.

Expanding Healthcare Infrastructure in Emerging Economies: Improved access to healthcare, especially in regions like Asia-Pacific and Latin America, is driving the demand for progesterone therapies.

Aging Population and Increasing Healthcare Investments: With an aging global population and rising healthcare investments, the demand for progesterone, particularly in managing conditions related to reproductive health and endometrial cancer, is expected to rise.

Key Market Opportunities:

Unmet Needs in Fertility Treatments: There is a significant opportunity for the progesterone market to cater to the growing demand for fertility treatments, particularly in assisted reproductive technologies (ART) such as IVF.

Increasing Adoption of Bio-Similars: The adoption of bio-similar progesterone therapies, which offer cost-effective alternatives to branded treatments, presents significant growth opportunities for market players.

Research & Development in Personalized Medicine: Advancements in personalized medicine, tailored to specific hormonal needs, create opportunities for developing targeted progesterone therapies, thereby driving market expansion.

Market Segmentation:

The global progesterone market can be segmented as follows:

By Type:

<ol> <li>Natural Progesterone</li> <li>Synthetic Progesterone</li> </ol>

By Modes of Delivery Source:

<ol> <li>Injectable</li> <li>Suspended Form</li> <li>Oral</li> <li>Intravaginal</li> <li>Others</li> </ol>

By Application:

<ol> <li>Regulation of the Menstrual Cycle</li> <li>Dysfunctional Uterine Bleeding</li> <li>Endometrial Cancer</li> <li>Contraception</li> <li>Others</li> </ol>

For more detailed market segmentation, access the full report at this link.

Key Players in the Progesterone Market:

<ol> <li>Sofgen Pharmaceuticals</li> <li>Pfizer Inc.</li> <li>Cipla Limited</li> <li>Lupin</li> <li>Aquatic Remedies Pvt. Ltd.</li> <li>Wuhan Honor Bio-Pharm Co., Ltd</li> <li>Shanghai Yijing Industrial Co., Ltd.</li> <li>Estrellas Life Sciences Private Limited</li> <li>Intas Pharmaceuticals Ltd.</li> <li>AdvaCare Pharma</li> </ol>

Regional Insights:

Dominated Region: North America holds the largest share of the global progesterone market. The region's advanced healthcare infrastructure, higher demand for hormonal therapies, and extensive research and development activities have contributed to its dominance.

Fastest Growing Region: Europe is expected to be the fastest-growing market for progesterone due to an increasing awareness of reproductive health, an aging population, and the rising adoption of hormone-based treatments.

For More Information or Queries

To request more information, ask for customizations, or inquire about purchasing the full report, visit: this link.

Straits Research continues to provide insightful, data-driven research reports designed to help industry players, investors, and stakeholders make informed decisions. With our comprehensive analysis and projections, stakeholders can plan for future market developments and capitalize on emerging opportunities in the progesterone market.

About Straits Research:

Straits Research is a leading market research and consulting firm that provides in-depth analysis of global industries, delivering insights into market trends, forecasts, and strategic growth opportunities. With a robust team of experts and comprehensive data-driven reports, Straits Research helps clients gain a competitive edge and drive business growth.

Contact Us

Email: sales@straitsresearch.com

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: UK: +44 203 695 0070, USA: +1 646 905 0080

[colinwilson11]

Soft Tissue Sarcoma Market To Grow Significantly Due To Increasing R&D Investment By Key Players

The soft tissue sarcoma market is a rapidly emerging field owing to increasing R&D investment by key players. Soft tissue sarcomas are rare cancers that develop in supporting or connective tissues like fat, muscle, blood vessels, deep skin tissues, and nerves. Some of the common types include gastrointestinal stromal tumors, uterine sarcomas, and rhabdomyosarcoma.

Soft tissue sarcomas account for about 1% of all adult cancers. While surgery is the mainstay for treatment of localized disease, advanced cases often require chemotherapy and targeted drug therapy.

The Soft Tissue Sarcoma Market is estimated to be valued at US$ 315 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the soft tissue sarcoma market are Pfizer, Eli Lilly, Johnson & Johnson, GSK (GlaxoSmithKline), and Roche.

The growing incidence of soft tissue sarcoma cases globally is a major factor driving market growth. Soft tissue sarcomas affected over 13,000 individuals in the United States in 2020 according to statistics.

Technological advancements like targeted drug therapy and development of biomarker assays are expanding treatment options and improving clinical outcomes for soft tissue sarcoma patients.

Market Trends

Increased focus on personalized medicine - Researchers are investigating molecular diagnostic tests and targeted therapies customized to a patient's tumor genetics which may improve response rates.

Combination therapy gaining traction - Combining drugs that work through different mechanisms is a promising approach and ongoing studies are evaluating combinations of chemotherapy with immunotherapies.

Market Opportunities

Immunotherapy emerging as a viable treatment option - Drugs that activate the immune system like checkpoint inhibitors have shown survival benefits in certain sarcoma subtypes creating new opportunities.

Companion diagnostics can guide therapy selection - Development of reliable biomarkers can help identify patients likely to respond to specific therapies and avoid treatment toxicity.

Impact Of COVID-19 On Soft Tissue Sarcoma Market Growth

The COVID-19 pandemic has significantly impacted the soft tissue sarcoma market. During the initial phases of the pandemic in 2020, most hospitals and clinics shifted their focus towards COVID care, which led to postponement of non-emergency surgeries and treatments. This impacted the diagnosis and treatment rates of soft tissue sarcomas. Patients also delayed their appointments and screenings fearing exposure to the virus in healthcare settings. This interrupted the continuity of care and follow-ups, posing challenges to sarcoma management. However, with increased availability of COVID vaccines and resumption of healthcare services from 2021, the market is slowly recovering. There is pent-up demand for diagnostic tests and treatments that were delayed during the peak pandemic phases. Hospitals have implemented strict safety protocols to reassure patients and ensure continuity of sarcoma management. Telehealth and home care services also aided in reducing disruption during lockdowns. Still, workforce shortages in the healthcare sector continue to pose operational difficulties. The long-term impact of delayed diagnoses and treatments remains to be seen. Market players are focusing on improving access to therapies through innovative drug delivery mechanisms and digital solutions.

Geographical Regions With Highest Soft Tissue Sarcoma Market Value

In terms of value, North America dominated the soft tissue sarcoma market as of 2021, owing to established healthcare infrastructure, high adoption of advanced diagnostic tools and therapies, and presence of key market players in the US and Canada. Within the region, the United States accounted for the major share. Europe is another prominent regional market, led by countries like Germany, United Kingdom, France, and others. Growing research on targeted therapies and partnerships between drug makers and cancer institutes are driving market growth across Europe. The Asia Pacific region is poised to be the fastest growing soft tissue sarcoma market over the forecast period due to rising healthcare expenditure, large patient population, and increasing awareness.

Fastest Growing Region For The Soft Tissue Sarcoma Market

The Asia Pacific region holds immense growth potential for the soft tissue sarcoma market and is expected to be the fastest growing region between 2024- 2031. This is attributed to factors like increasing healthcare access and spending in populous countries like China and India, rising incidence of sarcomas accompanying aging demographics, and improving diagnostic infrastructure. Furthermore, growing collaborations between global pharmaceutical companies and regional market players are boosting availability of advanced treatment options. Initiatives to spread awareness about rare cancers are also propelling regional growth. With economic expansion and growing focus on non-communicable diseases, the soft tissue sarcoma market is poised for strong growth across Asia Pacific.

Get more insights on this topic:  https://www.trendingwebwire.com/soft-tissue-sarcoma-market-is-estimated-to-witness-high-growth-owing-to-rising-rd-investments-in-immunotherapy/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

What Are The Key Data Covered In This Soft Tissue Sarcoma Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Soft Tissue Sarcoma's growth between 2024 and 2031.

:- Accurate calculation of the size of the Soft Tissue Sarcoma and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Soft Tissue Sarcoma Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Soft Tissue Sarcoma vendors

FAQ’s

Q.1 What are the main factors influencing the Soft Tissue Sarcoma?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Soft Tissue Sarcoma companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Soft Tissue Sarcoma’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[mrfr-blogs]

Market Outlook for Leuprolide Acetate Market Services

Market Overview –

The Leuprolide Acetate Market focuses on the production, distribution, and use of the medication Leuprolide Acetate, a synthetic hormone analogue used in the treatment of various medical conditions. Leuprolide Acetate is primarily prescribed for managing hormone-related conditions such as prostate cancer, breast cancer, endometriosis, and uterine fibroids.

One significant factor driving the growth of the Leuprolide Acetate Market is the increasing prevalence of hormone-dependent disorders and cancers. Prostate cancer and breast cancer are among the most common cancers worldwide, and Leuprolide Acetate is often prescribed as part of hormone therapy to reduce tumor growth and manage symptoms.

Additionally, Leuprolide Acetate is used in the treatment of gynecological conditions such as endometriosis and uterine fibroids, which affect millions of women globally. The medication helps alleviate symptoms such as pelvic pain, heavy menstrual bleeding, and infertility by suppressing estrogen production and inducing a temporary menopausal state.

The market for Leuprolide Acetate includes various formulations such as injectable depot formulations, subcutaneous implants, and nasal sprays, providing healthcare providers with options to tailor treatment regimens to individual patient needs. Additionally, generic versions of Leuprolide Acetate are available, offering cost-effective alternatives to branded formulations.

As healthcare systems strive to improve access to affordable and effective treatments for hormone-related conditions and cancers, the demand for Leuprolide Acetate is expected to continue growing. Pharmaceutical companies that innovate in drug delivery technologies, dosage forms, and formulations will remain competitive in this dynamic market, driving further advancements and opportunities for patients and healthcare providers alike.

The Leuprolide Acetate Market, also known as leuprolide injection market, is witnessing steady growth due to its widespread use in treating various conditions like prostate cancer, endometriosis, and uterine fibroids. Rising awareness about its efficacy and increasing prevalence of these conditions are driving market expansion.

The leuprolide acetate market is expected to reach USD 2,400 million by 2030, growing at a 10.50% CAGR during the forecast period 2022-2030.

Market Segmentation –

Globally, the market is segmented based on application, mode of administration, and end-users.

According to the application, the leuprolide acetate business is classed as prostate cancer, uterine fibroid in females, precocious, and many others.

According to the administration, the industry is separated into intramuscular and subcutaneous. The industry is divided into end-user segments such as hospitals, medical facilities, clinics, and others.

The market is segmented by end-users into medicals, clinics, research fields, and some academic institutions. According to the geographical study, the market is divided into several regions, including Europe, Asia, North America, and the rest of the globe.

Some companies' technology focuses heavily on research activities. Adopting technology in line with new leuprolide acetate market trends provides valuable insights that aid in the growth and development of the organization. Furthermore, technology assisted market players in achieving an optimal position in the industry.

Regional Analysis –

The regional analysis of the Leuprolide Acetate market reveals varying dynamics across different parts of the world. North America dominates the market, attributed to the high prevalence of conditions like prostate cancer and endometriosis, coupled with advanced healthcare infrastructure and favorable reimbursement policies. In Europe, the market experiences steady growth driven by increasing awareness about treatment options and rising healthcare expenditure. The Asia-Pacific region showcases significant growth potential due to improving access to healthcare, growing aging population, and increasing investments in healthcare infrastructure. Emerging markets in Latin America and Africa are also witnessing gradual market expansion as awareness about hormonal disorders and cancer treatment options increases, and healthcare systems continue to develop.

Key Players –

Analysis of the Leuprolide Acetate market's driving and challenging factors aids in refining marketing strategies to achieve competitive advantage. Competitors in the Leuprolide Acetate Market include COLMAR Pharmaceuticals, Pfizer Inc. (USA), Varian Pharmed (Iran), Merck kGaA (Germany), Avent AG (Switzerland), Abbott (USA), Takeda Pharmaceuticals Company Ltd (Japan), Astellas Pharma (Japan), Sun Pharmaceuticals Industries Ltd (India), Sanofi (France), Livzon Pharma Group Co. Ltd (China), AbbVie Inc. (USA), Beijing Biota Pharmaceuticals Co. Ltd (China), Soho-Filming (China), among others. Market growth is concentrated, prompting vendors to employ both organic and inorganic growth strategies for global competition. Company profiles highlight sustainability in production units and the rising prospectus rate of leading competitors.

Related Reports –

US Melanoma

Middle East and Africa HIV Diagnosis & Treatment

Gastroparesis Treatment

Dental Infection Treatment

For more information visit at MarketResearchFuture

[adorefem]

Gynaecology range Fertility to Menopause: Adorefem’s Gynaecology Range as a Beacon of Women’s Health

Introduction:

Adorefem emerges as a guiding light, offering a comprehensive and innovative Gynaecology range designed to address an array of female health concerns. As we unravel the layers of this nuanced landscape, we find a commitment to quality, a fusion of traditional herbal wisdom and modern medical breakthroughs, and a call to entrepreneurial spirits eager to explore the burgeoning Gynae drug market.

Adorefem stands at the forefront of women’s wellness, not merely as a pharmaceutical provider but as a partner in empowering women through every stage of life. This blog aims to shine a spotlight on the intricacies of Adorefem’s Gynaecology range, navigating through DCGI-approved drugs, herbal remedies, and groundbreaking innovations in hormone therapy. Join us as we explore the multifaceted dimensions of this realm, delving into the science behind the formulations and uncovering the potential for entrepreneurs in the ever-expanding Gynae drug market.

From Ovatrue’s micronized dehydroepiandrosterone blend to the herbal prowess of Angelica gigas, each product in Adorefem’s arsenal serves as a testament to the company’s unwavering dedication to advancing women’s health. As we traverse the landscape of gynaecological disorders, from infertility challenges to menstrual migraines, Adorefem’s offerings unfold as a tapestry of hope, providing solutions that extend beyond alleviating symptoms to enhancing overall well-being.

The blog transcends the medicinal realm to embrace the entrepreneurial spirit, inviting readers to consider the Gynae drug market not just as a business opportunity but as a venture into a segment that resonates with the evolving healthcare consciousness. Whether you’re seeking to start your own Gynaecology business or are intrigued by the prospect of being a distributor with independent monopoly rights, Adorefem beckons with promises of support, incentives, and a chance to contribute to the growing demand for reproductive healthcare solutions.

In the subsequent chapters of this exploration, we will navigate through the herbal marvels, hormonal innovations, and the promising landscape of the Gynae drug market. So, fasten your seatbelts as we embark on a journey that celebrates women’s health, entrepreneurship, and the groundbreaking contributions of Adorefem to the dynamic world of Gynaecology.

Understanding the Gynaecology Drug Landscape:

Adorefem takes pride in offering an extensive array of Gynaecology drugs, ranging from tablets and capsules to birth control pills and injectables. These drugs find applications in hormone replacement therapy, menopausal hormone therapy, and cancer treatment, among other areas. The emphasis on DCGI approved drugs underscores the company’s commitment to maintaining high-quality standards.

Gynae Product Range

Adorefem’s product lineup includes a range of meticulously formulated medicines designed to address various gynaecological concerns. Let’s explore some notable offerings:

Ovatrue:

A micronized combination of dehydroepiandrosterone (DHEA), vitamin D3, and folic acid.

Improves follicles, oocytes, implantation rates, and reduces neural tube defects.

Aptcal:

A blend of coral calcium, vitamin D3, and zinc.

Overcomes deficiencies to prevent fractures, post-menopausal osteoporosis, and supports pregnancy.

E2Care:

A natural blend of Cynanchun wilfordii, Phlomis Umbrosa, and Angelica gigas.

Relieves menopausal symptoms through various mechanisms.

Argirise C:

A combination of amino acids (L-arginine & L-citrulline).

Reduces systolic and diastolic blood pressure associated with pregnancy, improves uterine artery pulsatility indices and vascular functions.

Exploring Herbal Solutions:

Adorefem incorporates traditional herbal remedies into its product range, such as Angelica gigas and Cynanchun wilfordii. These herbs bring unique benefits, including anticancer and anti-inflammatory properties, addressing menopausal symptoms and irregular periods.

Innovations in Hormone Replacement Therapy:

The blog further explores innovative solutions like Beta Estradiol Gel, a topical medication offering relief for various gynaecological disorders such as dryness, itching, inflammation, and burning in the vaginal area. Clomiphene, another breakthrough, aids women facing infertility issues, especially those with polycystic ovary syndrome.

Comprehensive Gynaecological Solutions:

The Gynaecology drug list also includes medications for various gynaecological disorders, ranging from contraceptives and hormone therapy to preventing preterm birth and managing menstrual migraines.

Seizing Business Opportunities:

The blog transitions into the business aspect, highlighting the growing demand in the Gynae drug market. Adorefem encourages entrepreneurs to explore business opportunities in this segment, emphasizing the potential for growth due to increased awareness and spending on reproductive healthcare.

WHY CHOOSE ADOREFEM FOR GYNAE RANGE?

1. The Pillars of Excellence: Adorefem’s Commitment to Quality and Innovation

In the fiercely competitive landscape of Gynaecology pharmaceuticals, Adorefem distinguishes itself through a steadfast commitment to quality and innovation. Unraveling the layers of this pillar, we delve into the company’s dedication to DCGI-approved drugs, herbal integration, and cutting-edge hormone therapies. Adorefem’s focus on providing not just medications but holistic solutions positions it as a leader in setting new standards for excellence.

2. Navigating the Herbal and Hormonal Frontier: Adorefem’s Unique Approach to Women’s Health

Venturing beyond conventional pharmaceuticals, Adorefem’s Gynaecology range stands out for its integration of herbal wisdom and innovative hormone therapies. This section explores the herbal marvels like Angelica gigas and Cynanchun wilfordii, as well as the groundbreaking Beta Estradiol Gel. Adorefem’s ability to blend traditional remedies with modern medical advancements underscores its commitment to offering a diverse and comprehensive suite of solutions for women’s health.

3. Empowering Entrepreneurs: Adorefem’s Strategic Advantage in the Gynae Drug Market

For those aspiring to venture into the Gynae drug market, Adorefem presents not just an opportunity but a strategic advantage. This segment navigates through the unique proposition of independent monopoly rights, highlighting the freedom and control it affords to business associates. Adorefem’s support extends beyond this, encompassing robust marketing strategies, flexible investment plans, and attractive sales margins, providing a comprehensive package for entrepreneurial success.

4. Financial Inclusivity and Marketing Prowess: Adorefem’s Promise to Business Associates

A closer look at Adorefem’s commitment to its business associates reveals a blend of financial inclusivity and marketing prowess. This segment explores the reasonable and flexible investment plans, ensuring that the doors to the Gynaecology business are open to a diverse range of entrepreneurs. The provision of marketing tools at no additional cost adds a layer of support, underscoring Adorefem’s dedication to the success of its partners.

5. The Benchmark for Success: Adorefem’s Quality Assurance and Incentive Structure

In the competitive realm of pharmaceuticals, quality assurance is non-negotiable. Adorefem’s use of 100% pure raw materials and adherence to the highest standards of purity and efficacy set it as the benchmark for success. This section also delves into the incentive structure, emphasizing the company’s commitment to rewarding its associates for their dedication and contribution to the Gynae drug market.

6. Culmination of Excellence: Adorefem’s Pinnacle Position in Women’s Health and Wellness

As we reach the zenith of this exploration, the conclusion encapsulates the essence of Adorefem’s pinnacle position in women’s health and wellness. From its unwavering commitment to quality and innovation to its empowerment of entrepreneurs through strategic advantages and support systems, Adorefem emerges as not just a pharmaceutical provider but a visionary leader shaping the narrative of Gynaecology solutions.

In this culmination, we reflect on how Adorefem’s Gynaecology range transcends conventional boundaries, offering a narrative of empowerment, innovation, and comprehensive care for women. The company’s unique blend of traditional herbal wisdom, cutting-edge hormone therapies, and unwavering commitment to entrepreneurial success positions it as a trailblazer in the dynamic and evolving world of Gynaecology pharmaceuticals. As we bid farewell to this exploration, Adorefem stands tall as a beacon of excellence, beckoning entrepreneurs to join hands in reshaping the landscape of women’s health and wellness.

CONCLUSION

In every aspect, Adorefem stands tall as a beacon of excellence, beckoning entrepreneurs to join hands in reshaping the landscape of women’s health and wellness. As we bid farewell to this exploration, the echoes of Adorefem’s commitment to empowerment, innovation, and comprehensive care linger, leaving an indelible mark on the evolving narrative of Gynaecology solutions. Adorefem emerges as a visionary leader shaping the narrative of Gynaecology solutions. It goes beyond being a pharmaceutical provider, embodying a holistic approach to women’s health and wellness. The company’s unique blend of traditional wisdom, modern innovation, and unwavering commitment to entrepreneurial success positions it as a trailblazer in the dynamic and evolving world of Gynaecology pharmaceuticals.

Source: https://adorefem.medium.com/gynaecology-rangefertility-to-menopause-adorefems-gynaecology-range-as-a-beacon-of-women-s-health-6e3a72dde497

[dnaamericaapp]

FDA Proposes Ban Of Hair Relaxers With Formaldehyde

The Food and Drug Administration is proposing a ban on using formaldehyde as an ingredient in hair relaxers, a huge step in raising awareness about the potential harms these products create for the many Black women that typically use them.

The proposed rule would ban the chemical in hair-smoothing or hair-straightening products, also called relaxers. The FDA currently discourages consumers from using hair-straightening products that contain formaldehyde and similar ingredients, according to a fact sheet from the agency.

Formaldehyde is a colorless, flammable gas that’s used in a wide range of household products, including medicines and cosmetics, according to the Centers for Disease Control and Prevention. It’s highly toxic, and repeated exposure can cause irritation to the eyes, skin, lungs and throat. It is also linked to certain cancers, including myeloid leukemia, a cancer that occurs in the blood and bone marrow, according to the National Cancer Institute.

Even products that don’t contain formaldehyde as a main ingredient may contain other ingredients that, when heated, can be converted into formaldehyde, such as methylene glycol, which is found in some hair-straightening products. Some soaps, shampoos, lotions and cleaning products contain formalin, which is formaldehyde dissolved in water.

The current law does not require the FDA to approve cosmetic products and ingredients before they go on the market — only color additives, according to the agency’s website. Companies and individuals selling products have a legal responsibility to ensure the safety of their products, the agency says, but federal law and regulations don’t require companies to share their safety information with the FDA.

Research in recent years has helped raise awareness about the potential dangers of using chemical hair relaxers. The National Institutes of Health found that women who used hair straightening chemicals more than four times in previous year were more likely to develop uterine cancer. -(source: nbc news)

DNA America

“It’s what we know, not what you want us to believe.”

#dna #dnaamerica #news #politics

[rohans18]

Benign and Malignant Soft Tissue Tumors Treatment Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2029

Global Benign and Malignant Soft Tissue Tumors Treatment Market, By Types Benign Schwannoma, Desmoid Tumor, Lipoblastoma, Lipoma, Solitary, Uterine Leiomyoma, Clear Cell Sarcoma, Dermatofibrosarcoma Protuberans, Ewing Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Liposarcoma, Myxoid, Liposarcoma, Well Differentiated, Alveolar Rhabdomyosarcoma, Synovial Sarcoma, Others), Treatment (Medical Therapy, Surgical Therapy, Postoperative Therapy, Long Term Monitoring, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

In the consistent Benign and Malignant Soft Tissue Tumors Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Benign and Malignant Soft Tissue Tumors Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Benign and Malignant Soft Tissue Tumors Treatment market report brings precise and exact market research information that drives business into the right direction.

Key Players

Cyanotech Corporation (U.S.)

I.D. - Parry (India) Limited (India)

BlueBioTech International GmbH (Germany)

Algatech Ltd. (Israel)

Tianjin Norland Biotech Co., Ltd. (China)

AlgaeCan Biotech Ltd. (Canada)

AstaReal AB (Sweden)

Yunnan Alphy Biotech Co., Ltd. (China)

Fenchem (China)

Piveg, Inc. (U.S.)

��Browse More Info @ https://www.databridgemarketresearch.com/reports/global-benign-and-malignant-soft-tissue-tumors-treatment-market

The research studies entailed in the winning Benign and Malignant Soft Tissue Tumors Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Benign and Malignant Soft Tissue Tumors Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[techscitumbler]

The increasing prevalence of gynecological diseases and disorders among female population is the key driving force behind the growth of the Egypt gynecology drugs market. The rising incidence of these disorders is leading to a higher demand for gynecology drugs and treatments. For instance, cervical cancer has surfaced as one of the most common types of cancer affecting women in Egypt. According to the World Health Organization (WHO), Cervical cancer is the 6th most common cancer in women in the Eastern Mediterranean Region. In 2020, an estimated 89,800 women were diagnosed with cervical cancer in the Region and more than 47,500 women died from the disease. Moreover, according to the latest WHO data, published in 2020, the deaths caused by ovarian cancer reached 1,944 or 0.36% of total deaths in Egypt. The age-adjusted death rate is 5.11 per 100,000 population, placing Egypt at 61st position in the world. This has led to an increased demand for drugs and treatments to prevent and treat cervical cancer. Other gynecological conditions, such as breast cancer, ovarian cancer, endometriosis, and uterine fibroids, are also becoming more prevalent in the country, fueling the demand for drugs and treatments to manage and treat these conditions.

[martynnx-blog]

Uterine Cancer Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026

Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

Download PDF Brochure Of This Research Report @https://www.coherentmarketinsights.com/insight/request-pdf/1745

Uterine Cancer Drugs Market – Regional Analysis

Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.

Thus, uterine cancer drugs market is expected to exhibit significant growth in North America and Europe region, followed by Asia Pacific region. North America holds dominant position in uterine cancer drugs market, owing to the increasing incidence rate of endometrial cancer cases in these region. For instance, according to the International Agency for Research on Cancer: 2014 data findings, published by World Cancer Research Fund International, in January 2015, around 53% of the endometrial cancer cases were reported in developed economies, which includes U.S., Luxemburg, Norway, Poland, and among others. Moreover, according to the same source incidence of endometrial cancer was fond to be highest in Northern America and Europe and the lowest incidence in Africa and Asia. Furthermore, according to the data published in Journal of the National Cancer Institute in April 2018, North America, Eastern, and Northern Europe witnessed highest rate of endometrial cancer incidence and lowest rate were reported in middle-income countries including South Africa and India.

Uterine Cancer Drugs Market Competitive Landscape

Some of the key players operating in the uterine cancer drugs market include Merck & Company, Inc., Actiza Pharmaceutical Private Limited, United Biotech Pvt Ltd, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies, Inc. and among others.

[mrunalnerkarblog]

Specimen Retrieval Bag Market Rising number of acquisitions and collaborations by the market players are expected to boost growth of the market

Specimen retrieval bags are used in the laparoscopic (abdomen and pelvic) surgical procedures. These bags are designed to reduce contamination of the abdominal cavity during surgeries. These tear-resistant high-quality bags are mainly made of nylon and is coated by polyurethane. The specimen retrieval bag has an open end, closed end, and longitudinal axis for the collection of biological materials. It is a single use surgical instrument.

Market Dynamics

Increasing prevalence of gastrointestinal and uterine cancer, gynecological disorders, gall bladder stones, and hernia are expected to propel global demand for specimen retrieval bag over the forecast period. For instance, according to the American Institute of Cancer Research, endometrial cancer is the sixth most commonly occurring cancer in women and estimated 380,000 new cases were reported in 2018. Moreover, according to the same source, U.S., Canada, and Russia accounted for the 20.1%, 23.6 % and 18.7% per 100,000 population of endometrial cancer respectively in 2018.

Moreover, rising product approvals by the regulatory bodies is expected to propel the market growth over the forecast period. For instance, in November 2016, Covidien, a part of Medtronic received the 510(K) from the U.S. Food and Drug Administration (FDA) approval for ReliaCatch specimen retrieval bag of 10mm and 12 mm made from ripstop nylon and to be used in specimen retrieval.

Specimen Retrieval Bag Market - Regional Analysis

North America is expected to hold a dominant position in the global specimen retrieval bag market in 2018, owing to rising number of colon, pancreatic, and other cancer in the region. For instance, according to the article published in Gastroenterology Journal, 2018, around 139,773 new cases of colon and 46,477 of pancreatic cancer was estimated in the U.S. in 2014.

[peeterdbmr]

Uterine cancer is a type of cancer that occurs in the layers of the cells that forms the lining of uterus called endometrium. Symptoms include vaginal bleeding after menopause, pelvic pain and bleeding between periods. Uterine cancer can be detected at an early stage because it frequently produces abnormal vaginal bleeding and can be treated by removing the uterus surgically.

[nootropicsaustralia]

What does Fairtrade mean?

Everyone has seen the term Fairtrade on so many products. It immediately brings coffee, chocolate, tea and even bananas to mind. You may have seen it on the packaging of certain products or heard about it on their social media or website. You will probably recognise the logo for Fairtrade, and you'll know Fairtrade products are probably a good choice, and they do something right for people and the environment... but do you really know what it means.

SPILLING THE BEANS ABOUT FAIRTRADE COFFEE

With so many labels on products now, it’s hard to know when a symbol really means something. Fairtrade means something. It is not a marketing gimmick for companies to increase prices. Instead, Fairtrade is precisely what these two words promise. It is fairness, in a tradeable product.

However, fairness for whom? It is fairness for the producers, the manufacturers and YOU - the consumer.

This post will spill the beans about Fair trade and provide FIVE reasons why we all should support Fairtrade products.

But first, let’s make sure we’re on the same page with what Fairtrade actually means...

WHAT IS FAIRTRADE?

Fairtrade seems like a bit of a no brainer. It covers responsibly sourced products. Who wouldn't enjoy their coffee a little bit more knowing the farmers that grew it, and the people that roasted it were fairly treated! Fairtrade certification means that products have gone through a rigorous test to ensure they have followed the Fairtrade standards. The Fairtrade movement initially began in the 1950's and has been developing and improving since that time.

The Fairtrade standards encourage social, economic and environmental development for farmers and workers. Moreover, worker rights are ensured with the prohibition of forced labour and child labour. These standards fulfil six of the United Nations Sustainable Development Goals:

No poverty

Gender equality

Clean water and sanitation

Decent work and economic growth

Responsible consumption and production

Life above water (1)

In fact, Fairtrade may be larger than you think. Fairtrade producers operate in 75 countries and territories! There are 30, 000 available Fairtrade products and 1.7 million farmers and workers involved in Fairtrade around the world. (2)

Producers of Fairtrade products are paid a Fairtrade Minimum Price and Fairtrade Premium sums. The Fairtrade Minimum Price is the lowest amount of money that Producers can be paid for their products and remain the same even when market prices drop. They can also get the local market price if this is higher than the Fairtrade Minimum Price.

The Fairtrade Premium is an extra sum of money which farmers and workers use to invest in the improvement of their businesses and communities. This sum can be used to build a hospital, purchase better farming equipment and even transition to organic farming! (3)

Okay - and now for the given reasons you should care about Fairtrade and make the switch...

1. Empowerment of producers and workers

Fairtrade empowers producers to have a voice to ensure that their needs are addressed and prevent exploitation.

Fairtrade organisations aim to eliminate poverty which closely aligns with the first goal of the United Nations Sustainable Development Goals. Workers can form a committee, participate in the board of directors and act as consultants so they can influence Fairtrade’s strategy, standards, prices and premiums. Fairtrade places the worker and consumer at the heart of its core values. Workers are protected from the worst effects of market volatility and have access to capital which they can use to improve the quality of their lives. They can even use their Fairtrade Premium pay to receive financial advice on contracts.

Some of the core elements of the Fairtrade standards are training opportunities, non-discriminatory employment practices, adequate occupational safety and health conditions, and sufficient facilities for the workforce.

Moreover, the Fairtrade Standards is slowly fulfilling the sixth goal in the United Nations Sustainable Development Goals - clean water and sanitation for all individuals. The Fairtrade standards stipulate that working environments and facilities must have accessible clean water and adequate sanitation facilities. These facilities must be provided if the worker’s housing is provided by the employer.

2. Equality across genders and generations

The Fairtrade standards contain explicit requirements for workplace policies around sexual harassment and discrimination. All workers must receive equal pay and representation in the leadership and decision making power regarding the investment of Community Development Funds.

Example 1 (4)

Koperasi Kopi Wanita Gayo (KKWG) coffee farming organisation is the first all-women coffee cooperation in South East Asia and Fairtrade certified. Most members found that they were able to express their voices and concerns more freely in KKWG than in other cooperatives dominated by male members or working beside their husbands.

KKWG is composed of 470 members and sold more than 13 metric tonnes of coffee on the Fairtrade market in 2015. Previous to KKWG’s establishment in 2014, the members knew nothing about coffee roasting nor how to improve cultivation. Now, these women are being empowered to develop new skills. They spent their first Fairtrade Premium on cupping training and education on how to increase soil fertility.

Members attribute to their rising sales due to their Fairtrade certification and combined with their good connections in the industry, KKWG will continue to prosper.

Example 2 (5)

Wendy Rodriguez is the voice and face of Acopagro, a Fairtrade and organic cocoa cooperative. For more than 20 years, Acopagro has been helping its farmers to make their own way out of poverty in Northern Peru. Due to Fairtrade, farmers have electric lighting but running water is still on the agenda and is dependent on enough Fairtrade Sales. Prior to the founding of Acopagro, there was no cocoa and only cocaine. Farming families suffered from illegal drug trafficking, violence and threats. Wendy’s father worked in a bank where drug-trafficking money was laundered and killed after a militia raided her family’s home. However, Acopagro has helped to transform this formerly violent and drug-ridden community in Northern Peru. Last year, 1600 members of Acopagro took eyesight tests and 950 women participated in a health campaign for the prevention of uterine cancer.

Example 3 (6, 7)

Women in Business Development empowers village economies to honour tradition and yet combine with modern technology while promoting fairtrade. This organisation works in 183 Samoan villages and incubates certified organic farming enterprises to improve the lives of individuals in this community. For instance, WIB supports women in Samoa to plan for the future of their daughters and their own. Coconut products are intergenerational businesses as they take six to ten years to start fruiting and peak production occurs at least 15 years. By developing a sustainable and Fairtrade business, these individuals are able to maintain a long-lasting and secure livelihood.

In essence, Fairly traded products enable women to earn equal amounts of pay from their male counterparts and access more financial opportunities.

3. Environmental impact

Fairtrade certified producers must follow environmentally sound agriculture practices. They must have minimised and safe use of agrochemicals, proper and safe management of waste, maintenance of soil fertility and water resources, AND no use of genetically modified organisms.(8)

Producers do not need to be organically certified but the Fairtrade organisations promote organic production and there is a higher Fairtrade Minimum Price for organically grown products. The Fairtrade Minimum Price helps to cover the costs of sustainable production and reduce the financial strain on producers.

4. Market opportunity for manufacturers

Fairtrade products are the most recognised ethical label in the world. There is an increasing trend of consumers and businesses seeking out sustainable sourced products. Moreover, consumers have a more positive opinion of a product solely due to the label Fairtrade. According to 2015 GlobeScan research, eight in ten consumers say the Fairtrade mark has a position impact on their prescription of the brand. Moreover, Fairtrade has a global network of marketing organisations that can extend a manufacturer’s reach.

Stable trading partnerships can be formed between the supplier and the manufacturer. Long-term business relationships can be facilitated as there is a mutually beneficial positive trade exchanged between these two parties.

Fairtrade Theory of Change

Image credit: Fairtrade USA's Theory of Change (9)

5. Consumer

Fairtrade is a smarter and ethical choice. Consumers can be assured that the workers and producers are not exploited in the manufacture of this product. Some businesses reduce the wages of workers to competitively compete in the market. Fairtrade certification prevents this unsavoury business practice. Moreover, consumers will be supporting social, economic and environmental change through their purchase of Fairtrade product(s). Fairtrade manufacturers must ensure a sustainable transparent production of a service/product.

WE OFTEN DON’T HEAR ABOUT THE ADVANTAGE OF FAIRTRADE LIVING IN AUSTRALIA, BUT NOW THAT YOU KNOW THE IMPORTANCE, LOOK FOR THE FAIRTRADE LOGO.

In essence, Fairtrade products allow investment for the future. Producers can improve their livelihood and quality of life through the Fairtrade Premium wage.

Savvy Beverage’s Mental Performance Coffee pods is an Australian Fairtrade product that provides longer lasting energy, boosts mood and reduces stress! The coffee beans are sourced from Fairtrade, sustainable and ecological farms.

Savvy is a proud supporter of Fairtrade, and of our farmers. We ensure that our product is socially responsible.

Consumers can rest assured that the workers and producers can receive an adequate and fair price for their goods (i.e. Fairtrade Minimum Price). Fairtrade standards promote social justice, equality and human rights.

Now you've learned the importance of Fairtrade, so please look out for the logo and choose Fairtrade.

[snehalaxel]

Gynecological Cancer Drugs Market 2021 Global Leading Key Players, Trends, Share, Industry Size, Sales, Supply, Demand, Analysis and Forecast to 2027

"

Gynecological Cancer Drugs Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://axelreports.com/request-sample/34175

A 360 degree outline of the competitive scenario of the Global Gynecological Cancer Drugs Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers seven-year assessment of Global Gynecological Cancer Drugs

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers regional analysis of Global Gynecological Cancer Drugs Market along with business profiles of several stakeholders.

It offers massive data about trending factors that will influence the progress of the Global Gynecological Cancer Drugs

Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-gynecological-cancer-drugs-industry-production-sales-and-consumption-s/34175

By Market Players: Apotex AstraZeneca Bristol-Myers Squibb Eli Lilly F. Hoffmann-La Roche GlaxoSmithKline Merck Novartis Pfizer Teva Pharmaceutical Industries By Type Chemotherapy Targeted Therapy Hormonal Therapy By Application Uterine Cancer Ovarian Cancer Vaginal Cancer Cervical Cancer

A detailed outline of the Global Gynecological Cancer Drugs Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Gynecological Cancer Drugs Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Gynecological Cancer Drugs Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Gynecological Cancer Drugs Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/34175

Table of Contents:

Global Gynecological Cancer Drugs Market Overview

Economic Impact on Industry

Market Competition by Manufacturers

Production, Revenue (Value) by Region

Production, Revenue (Value), Price Trend by Type

Market Analysis by Application

Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global Gynecological Cancer Drugs Market Forecast

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: sales@axelreports.com/ Web: https://axelreports.com/

"

[destroyyourbinder]

A few more very interesting things from that well-researched Medium piece, about the pharmaceutical world's investment in hormone replacement therapy and the timing of transgender advocacy's inroads into public activism, including a connection to the controversy about menopause-related HRT which ended the widespread marketing of Premarin to aging women that I had failed to notice, the lucrative dynamics of promoting and prescribing drugs off-label (all transgender HRT is given off-label), the absolutely absurd amount of money in hormones for pediatric transition (the author gives numbers for Lupron from age 10 to 16, which in the US costs multi-thousands of dollars), and the entanglements of some of the most notable pediatric transgender doctors with pharmaceutical companies producing these drugs : The most common use for HRT over the 20th century was instead [of treating transgenderism] to treat menopause. That particular train derailed in 2002, when the National Institutes Of Health’s Women’s Health Initiative, a large clinical trial to test HRT’s safety and efficacy, found out that HRT in women led to raised rates of strokes and breast cancer among other deleterious side effects. Lawsuits, particularly against the pharmaceutical company Wyeth (purchased by Pfizer in 2009), quickly followed, and the number of prescriptions of one of Wyeth’s most profitable medications dropped 66%. Overnight, HRT for menopause was no longer understood to be the automatic course of action. It later emerged that Wyeth and other drug companies marketing HRT had known about the risks but had deliberately concealed them to continue selling profitable drugs. This caused some issues for pharmaceutical companies. Premarin, manufactured by Wyeth, was the best-selling drug of the 90s. HRT became accepted by women and physicians alike, and HRT was encouraged as safe and effective for menopause — which was untrue. It has been described as a time when patients request the medication, and physicians prescribed it, without checking on whether this medicalization of a natural process was needed or not. 42% of American women between the ages of 50 and 72 were on some form of HRT in 1999. Yet clinical trials instead proved that HRT was dangerous, and that the risks outweighed the benefits. And the prescription of HRT for menopause ended almost as quickly as it started. Pfizer, which makes the estrogen drug Premarin after purchasing Wyeth in 2009, is a major corporate partner of the Human Rights Campaign (HRC) and received a 100% score on the HRC’s Corporate Equality Index. Wyeth was no stranger to targeting minorities for drug experimentation. [...] Wyeth again engaged in unethical behavior with Prempro, another estrogen hormone replacement therapy drug, which is also used for transition. Wyeth used ‘medical ghostwriters’ to build a brand around Prempro and various off-label uses of the drug. What’s medical ghostwriting? Essentially, it’s a pharmaceutical company producing a peer-reviewed article promoting use of a drug it makes, often for off-label uses.This is done by hiring a commercial medical writing company to produce papers that can then be published in academic journals. An academic is attributed authorship, even though they have not written the paper. The paper contains conclusions that support the pharmaceutical company’s marketing desires for a particular drug. In the case of Prempro, legal documents that emerged from a lawsuit brought by 14,000 patients were released to PLoS Medicine, an open access journal (viewable here). It revealed that Wyeth hired a medical communications company, DesignWrite, who then produced a first draft of a paper, received advice on a second draft from Wyeth, then sent it to an academic who would ‘author’ the paper by attaching their name and claiming authorship. Typically, the papers are review articles — they review a body of literature on a particular drug, then draw conclusions on its use. While the academics weren’t paid, political currency in academia has become the number of papers published in journals, so it added to their credentials. DesignWrite sold over 50 articles to Wyeth about HRT and produced conference posters and symposia materials. The material produced by DesignWrite promoted off-label uses of HRT. DesignWrite also promoted its advisory board creation and management capabilities to pharmaceutical companies. While medical ghostwriting is clearly unethical, it’s not illegal. Because academic publications aren’t considered promotional, it does not fall afoul of off-label marketing laws. Pharma companies can ghostwrite as many articles as they like, building a message that the off-label use of drugs is safe, acceptable. They then publish that in an academic journal. Wyeth would produce studies that sang the praises of HRT for things it could never market it for, like curing wrinkles. Because the fact that the paper is ghostwritten is never disclosed, it means that people could potentially be receiving biased information that favors a drug company and using that when making decisions around patient health. If a large body of ‘research’ is promoting a use for a drug, then it must work, right? How prevalent is medical ghost-writing,? The New York Times estimated in 2009 that 5–11% of medical articles are ghostwritten, though this ultimately depends on the drug. With one drug (sertraline), between 18% and 44% of articles on the subject were funded and ghostwritten by Pfizer. But without disclosure, we do not know how prevalent the problem might actually be. Disturbingly enough, similar evidence is beginning to come out regarding HRT in men, who have been sold similar stories about ‘Low T’ and testosterone therapy. Unlike HRT in women, this has not come through a large drug trial, but nearly 7,000 lawsuits, directed at the makers of low testosterone treatments. Side effects include strokes, elevated risk of heart attack and blood clots. In fact, the makers of Androgel, AbbVie, were ruled against in a lawsuit brought by one Jesse Mitchell, described as a ‘bellwether’ case, to the tune of $150 million, for misrepresentation of the safety of their testosterone gel, Androgel. Mitchell suffered a heart attack after four years of using the gel, which was ruled to be directly caused by the Androgel treatment. AbbVie aggressively marketed Androgel on television, despite the fact that testosterone treatments were causing elevated rates of heart attacks. The $150 million lawsuit was later tossed, but a second trial again ruled against AbbVie, awarding Mitchell $3.2 million . 4,500 of the nearly 7,000 lawsuits involve AbbVie’s Androgel, which is considered the ‘Low T’ market leader. It is notable that AbbVie promoted the Androgel drug off-label. In fact, a former FDA head, David Kessler, told jurors in an another testosterone lawsuit, that he believes that AbbVie illegally promoted the testosterone supplement to aging men, without testing the safety of doing so. To quote his testimony: “What the companies in essence did was to take those indications of low testosterone in men for specific reasons [and] the company in essence broke that link,” “It was no longer [being marketed] for specific diseases; it was for low testosterone for a broad range of issues.” The drug companies pushed to market the drug off-label, regardless of whether ‘Low T’ was a scientifically valid condition or simply the natural aging process. What relevance this does have to the transgender movement? Hormone Replacement Therapy is the primary drug prescribed for the treatment of transgenderism. It has a long history of illegal marketing, medical ghostwriting, and unethical behavior towards vulnerable patients.Many of these same side effects have been reported in transgender people who take these drugs. For example, it is well known among female-to-male transgender people that after long periods on testosterone they require a hysterectomy, as they have higher risks for uterine cancer. They also frequently experience incontinence and vaginal prolapse. Many trans women experience heart attacks and strokes. These side effects have been dismissed as hormone therapy is ‘necessary’ — so that this population don’t kill themselves. [...] HRT is prescribed and intended for the patient to take for life as they begin a journey into being their ‘authentic self’. A transgender person expects to take hormones for the rest of their life. This is significant because every drug prescribed for transgenderism is prescribed off-label. There are no approved drugs for treating transgenderism. Not puberty blockers, nor HRT. For transition, many of the drugs used by transgender people are common brand name HRT drugs that are being used off-label. Premarin, Androgel, and others. All of these drugs have histories of off-label marketing. Androgel as aforementioned has thousands of lawsuits pending against it. This history of pharmaceutical companies using illegal marketing practices and ignoring deleterious side effects can’t possibly be the case with transgender use, can it? Stephen Rosenthal, former president of the Pediatric Endocrine Society and transgender scientist media star and one of the primary researches on transgenderism describes this off-label status as a hurdle for puberty blockers in an article in Endocrine Today: “One critical issue at this point in time is that none of the options for pubertal blockers on the market are FDA approved for transgender use. No pharmaceutical company has taken the steps necessary to change their labelling to include this category.” A look through the names of the scientists that study and promote transgenderism and the use of HRT to treat it, and you will see Rosenthal’s name repeatedly. You will also see other names repeatedly, particularly in transgender children research, and you will find the same group of people are always responsible for such research, such as Dr. Norman Spack, of Boston’s Children’s Hospital and Robert Garofalo, from Lurie Children’s Hospital in Chicago. Many of them only began producing research on transgenderism, particularly in children, during the past decade. For example, Rosenthal’s publications are on topics such as insulin metabolism until 2012, when his entire output becomes focused around transgenderism. [...] Oh, here’s a fun fact the article [A PBS interview with pedriatric gender doctor Robert Garafalo] also includes: “Most of these treatments are still very expensive and often out of reach for people without the help of insurance. The cost of puberty blockers is approximately $1,200 per month for injections and can range from $4,500 to $18,000 for an implant. The least expensive form of estrogen, a pill, can cost anywhere between $4 to $30 a month, according to Simons, while testosterone can be anywhere between $20 to $200 a vial.”Using these figures, and taking a ten-year-old child, the total cost of transition for a ten-year-old who takes puberty blockers until they are 16, is $86,400. There are 725 children being treated for gender dysphoria at Lurie’s, which gives us a figure of $62 million dollars over 6 years in Lupron prescriptions were all those 725 children starting to take puberty blockers right now. Transition is an expensive business. [...] Let’s look at three doctors in particular. Their names are Dr. Diane Ehrensaft, Stephen Rosenthal, and Johanna Olson. Why?All three of those names have had a financial relationship with AbbVie, maker of Androgel and Lupron, amongst other hormone replacement therapies and GnRH agonists. All three have gone on to promote the off-label use of AbbVie products to treat transgenderism. Both Joanna Olson and Diane Ehrensaft attended an AbbVie advisory board on gender care, Olson in 2015 and Ehrensaft in 2014. Olson discloses this as a conflict of interest in the paper Care of a Transgender Adolescent Commentary, which was published July 2015 — she attended this advisory board after submission and was compensated for attending. Olson then continued promoting off-label use of AbbVie drugs. Diane Ehrensaft does not declare this as a conflict of interest on any research papers, but it appears in her Curriculum Vitae (scroll to page 16), which she submitted to court while an expert witness, and is hosted on her website. Her CV reports, that in 2014, she was a board member of the ‘AbbVie Trans Advisory Board’, while promoting their drugs for off-label use in transgenderism, both in academia and through popular science books she wrote, such as The Gender Creative Child. Was she compensated for being on this advisory board, like Olson? Stephen Rosenthal frequently discloses that he is a consultant for AbbVie as a conflict of interest in both interviews and research, and then continues to promote the dangerous off-label use of their medication in adolescents. Why is this concerning? The Center for Medicaid and Medicare Services advises that among the methods of spotting unlawful, off-label promotion, is paying physicians to serve as advisory board members.

[aartichede08]

Women’s Health Therapeutics Market Share, Growth Strategy, Trend Analysis, And Forecast 2028

Women are more prone to certain diseases, mostly related to menstrual disorders, depression, osteoporosis, obesity, and autoimmune diseases. Women's major health issues are related to the reproductive system that includes infertility, polycystic ovarian syndrome, menopause, and cancers such as breast cancer, cervical cancer, and urological disorders. Chronic diseases, such as heart disease, cancer and stroke, cause more death, illness and disability in the United States than any other cause.  As indicated by, Centers for Disease Control and Prevention (CDC) each year, more than 1.7 million Americans die from a chronic disease, accounting for seven out of every 10 deaths. While chronic disease is the leading cause of death for men and women alike, women face unique health challenges. Thirty-eight percent of women suffer from one or more chronic diseases, compared to 30 percent of men.

To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/hc1971-womens-health-therapeutics-market-report

WOMEN’S HEALTH THERAPEUTICS MARKET OUTLOOK

Global women’s health therapeutics market has been growing at a phenomenal pace in the past few years due to increasing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders, high adoption of diagnostics imaging procedure and high prevalence of chronic diseases such as HIV,  Urinary incontinence, Breast cancer in women across the globe. For Instance, As indicated by Phoenix Physical Therapy, Urinary Incontinence affects 200 million people worldwide of the 25 million adult Americans suffering from some form of urinary incontinence, 75-80% of those are women. In addition, rising number of menopausal conditions amongst women coupled with the changing lifestyles and poor dietary habits and growing investment by key market players to fulfil demand in areas of infection, cancer, and pregnancy-related complications are also expected to boost the women health therapeutics market. 

WOMEN’S HEALTH THERAPEUTICS MARKET SEGMENTAL OVERVIEW

The global Women’s Health Therapeutics Market is segmented by Treatment Type, Disease Indication and Geography.

WOMEN’S HEALTH THERAPEUTICS MARKET BY TREATMENT TYPE

Based on treatment type, the market is categorised into Hormonal Treatment and Non-Hormonal Treatment. Hormonal treatment segment is further categorised into Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, and others. Further on, Non-Hormonal Treatment segment comprises Cancer Targeted Therapy Drugs, Antibiotics, Bisphosphonates and others.

The market for the Hormonal treatment has recorded positive inclining growth due to growing demand for postmenopausal hormone therapy. The non-hormonal treatment has comparatively least efficacy to produce optimum results. However the risk of breast cancer associated with the hormonal products has boosted the demand for non-hormonal pharmaceutical products.

WOMEN’S HEALTH THERAPEUTICS MARKET BY DISEASE INDICATION 

Based on disease indication, the Global Women’s Health Market is bifurcated into Cancer, Hypothyroidism, Post-Menopausal Syndrome, Osteoporosis, Contraceptive, Uterine Fibroid, Urinary Tract Infection and others.  The Cancer segment comprises of Breast Cancer, Cervical Cancer and Ovarian Cancer.  The demand for breast cancer therapeutics is growing due to the high prevalence of breast cancer across the globe. Breast cancer is the most frequent cancer among women. As per World Health Organisation Data, breast cancer is impacting 2.1 million women each year.  In 2018, it is estimated that 627,000 women died from breast cancer. The breast cancer mortality rate is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.

WOMEN’S HEALTH THERAPEUTICS MARKET BY GEOGRAPHY

The Women’s Health Therapeutics Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global Women’s Health Therapeutics Market in 2018. The large share of the market is attributed to the factors such as the rising incidence of breast cancer coupled with the easy accessibility and high adoption of advanced diagnostic technologies, significant per capita annual healthcare expenditure in the US and Canada, and the rapidly increasing geriatric population in the region. Further, growing incidence of lifestyle related health disorders, rising focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and increasing demand for fertility testing monitors are also the major factors attributed to the growth of the market.

However, the Asia-Pacific market is expected to grow at the highest CAGR during the forecast period. A number of factors, such as the growing patient populace, improving healthcare infrastructure, rising government spending on breast cancer research studies, growing healthcare expenditure and implementation of several initiatives to create awareness about the early detection of breast cancer are expected to drive the market in the Asia-Pacific region during the forecast period.

WOMEN’S HEALTH THERAPEUTICS MARKET KEY PLAYERS

Some of the key players operating in the global Women’s Health Therapeutics Market are Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, Bayer AG, GlaxoSmithKline plc, and Johnson & Johnson among others.

Buy now Women’s Health Therapeutics Market Report https://www.axiommrc.com/buy_now/hc1971-womens-health-therapeutics-market-report

About Us:

Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc. 

Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.

Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.

Contact Us:

Axiom Market Research & Consulting™

3 Germay Dr. Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com

Website: https://www.axiommrc.com/

Blog: https://industrywatch24.com/

Follow On

LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/

Twitter:  https://twitter.com/AxiommrcCom